Trial intelligence / Profile preview

Pristinamycin vs Amoxicillin in Acute Community Acquired Pneumonia

NCT02332577Phase 4Terminated

Sponsor
Sanofi
Start
Apr 2015
Primary completion
Feb 2023
Modality
Small Molecules
Countries
2
01

Overview

Phase 4, randomised, double-blind trial of pristinamycin in community acquired pneumonia (CAP) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of patients cured established from the clinical course and pulmonary radiological course. Started Apr 2015; status: terminated.

02

Drugs

pristinamycin
03

Conditions

community acquired pneumonia (CAP)

Beyond the preview

Go deeper on NCT02332577.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02332577.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call